24 October 2018, Dunfermline, Scotland; Optos Plc, a subsidiary of Nikon Corporation, Japan and the only ultra-widefield retinal imaging company for eye care is pleased to announce an exclusive distribution agreement in Europe and Australia for MacuLogix and LumiThera products. By entering this arrangement, we now offer a comprehensive solution to visualize, identify, and treat age-related macular degeneration (AMD), one of the leading causes of blindness in the world.

This three-part offering includes ultra-widefield optomap colour and autofluorescence retinal images to show the structure and function of the retinal pigment epithelium (RPE) where AMD manifests within the eye. The MacuLogix AdaptDx, a dark adaptometer that can be used to detect AMD at a subclinical stage at least three years before structural changes such as drusen are visible. And the LumiThera’s ValedaTM Light Delivery System, the first approved for treatment for dry age-related macular degeneration using photobiomodulation.

“We are pleased to enter this relationship with MacuLogix and LumiThera to combat AMD. This strategic solution to monitor and treat AMD is very important for the patients who have this complicated, degenerative disease”, stated Robert Kennedy, Chief Executive Officer, Optos. “We believe these two companies have complementary products to ultra-widefield retinal imaging that would provide a differentiated offering for AMD patients. The MacuLogix device can early diagnose AMD and the LumiThera medical device offers a differentiated treatment path”.

“Optos is one of the largest and most-respected suppliers of retina-focused medical devices in the world and MacuLogix is extremely honored to enter into this international partnership with them,” said William McPhee, President and CEO of MacuLogix. “By expanding our distribution network to include these eight countries, the AdaptDx will reach an additional 260 million people. Partnering with the Optos team gets us one step closer to our company’s vision of eliminating blindness caused by AMD.”

Clark Tedford, Ph.D., LumiThera President and CEO stated, “The distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area. Optos is the global leader in ultra-widefield retinal imaging technologies and we are honored to be working with them to open up a new age in the treatment of AMD.”

原文链接：https://www.lumithera.com/optos-announces-collaboration-for-monitoring-and-treating-dry-age-related-macular-degeneration-in-europe/